Sg001
Clinical Trials Overview
3 trials found
About Sg001
SG001 is an experimental therapeutic compound that appears to be designed for combination therapy in colorectal cancer treatment. Based on clinical trial data, it is being evaluated alongside hypofractionated radiotherapy and PD-1 antibody therapy for locally recurrent rectal cancer. The drug represents a novel approach to enhancing treatment responses in advanced colorectal cancer patients who have limited therapeutic options.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
The specific molecular mechanism of SG001 has not been fully disclosed in available clinical data. Given its use in combination with PD-1 inhibitors and radiation therapy, it likely functions as an immune system modulator or sensitizing agent that enhances the efficacy of concurrent treatments.
3
Total Trials
1
Recruiting
0
Active
1
Completed
314
Total Enrollment
1
Countries
Active sites for Sg001
Recruiting sites
1 countries
Phase:
NCT07183865
Phase 2
Recruiting
44 patients
This is an open-label, single arm, phase 2 study. The study is to evaluate the activity of combination therapy of hypofractionated radiotherapy, Irinotecan Hydrochloride Liposome plus 5-FU and leucovorin (NALIRIF), Anti-PD1 and target therapy in pati...
China
NCT06132217
Phase 1
Not yet recruiting
168 patients
Medications:
SG001
Simmitinib
This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 ...
China
NCT06089330
Phase 2
Completed
102 patients
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).